thumb
May 9, 2022

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE  UNDER THE ACCELERATED APPROVAL PATHWAY

TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has completed the rolling submission to the U.S.

thumb
March 28, 2022

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies

thumb
March 21, 2022

Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting

TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Aβ)

thumb
March 18, 2022

The National Minority Quality Forum and Biogen Highlight Equitable Access to Research and Care in Real World Evidence White Paper

The National Minority Quality Forum (NMQF) and Biogen will today discuss the importance of generating real-world evidence on a webinar hosted by NMQF on equitable access to research and care. Together, the organizations have also issued a white paper highlighting how real-world evidence (RWE) is

thumb
March 17, 2022

Biogen to Participate in the Stifel 2022 CNS Days

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Global Safety and Regulatory Sciences and Interim Head of R&D, will participate in the Stifel 2022 CNS Days. The webcast will be live on Monday, March 28, 2022, at 10:15 a.m. ET.

thumb
March 16, 2022

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM ®  (aducanumab-avwa) 100

thumb
March 16, 2022

Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years

ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half years Data from both Phase 3 studies also show that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks These

thumb
March 14, 2022

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023 Lecanemab collaboration to continue unchanged globally Lecanemab supply agreement to extend to 10 years from 5 years for commercial manufacturing by Biogen

thumb
March 14, 2022

Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi ® (risdiplam) Baseline characteristics indicate all nine infants and toddlers enrolled in RESPOND had suboptimal

thumb
March 11, 2022

Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for intravenous use, at the upcoming International Conference on Alzheimer’s and

thumb
March 4, 2022

EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB

TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices